DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS

炭疽疫苗制剂的开发

• 批准号: 9430241
• 负责人: JOHN TROYER
• 金额: $ 402.84万
• 依托单位: PHARMATHENE, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-10 至 2024-01-05
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9430241
• 关键词: Advanced Development; Anthrax Vaccines; Categories; Cold Chains; Communicable Diseases; Development; Disease Outbreaks; Event; Formulation; National Institute of Allergy and Infectious Disease; Technology; Vaccines; pathogen; response; vaccine development

The primary objective of this project is to support the advanced development of candidate products which consist of a vaccine component in combination with a technology component (a dry formulation technology) to increase stability and minimize cold chain or preservative requirements for use in post-event settings following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens.

该项目的主要目标是支持候选产品的高级开发，这些产品由疫苗成分和技术成分组成（干制剂技术），以增加稳定性并最大限度地减少冷链或防腐剂要求，用于故意释放或应对自然发生的由NIAID A、B类引起的传染病爆发后的事后环境，C优先病原体